Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: An open-label, parallel-group, single-dose study

Clinical Therapeutics

Volumn 33, Issue 11, 2011, Pages 1798-1808

  Kasichayanula, Sreeneeranj ^a   Liu, Xiaoni ^a   Zhang, Weijiang ^a   Pfister, Marc ^a   LaCreta, Frank P ^a   Boulton, David W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Dapagliflozin; Hepatic impairment; Pharmacokinetics; SGLT2 inhibitors; Special populations

Indexed keywords

DAPAGLIFLOZIN;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BACKACHE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LIVER DISEASE; MALE; PHLEBITIS; PHYSICAL EXAMINATION; RASH; SINGLE DRUG DOSE; SMOKING;

ADULT; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORT PROTEINS;

EID: 82855162710     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.09.011     Document Type: Article

References (30)

1. IDF diabetes atlas. International Diabetes Federation Accessed February 16, 2010. http://www.diabetesatlas.org/.
2. Diabetes facts. World Diabetes Foundation Accessed September 1, 2010. http://www.worlddiabetesfoundation.org/composite-35.htm.
3. DeFronzo R.A. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004, 88:787-835. ix.
4. Weyer C., Tataranni P.A., Bogardus C., Pratley R.E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care 2001, 24:89-94.
5. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
6. Cheung B.M., Ong K.L., Cherny S.S., et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009, 122:443-453.
7. Marsenic O. Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009, 53:875-883.
8. Han S., Hagan D.L., Taylor J.R., et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008, 57:1723-1729.
9. Meng W., Ellsworth B.A., Nirschl A.A., et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008, 51:1145-1149.
10. Ferrannini E., Ramos S.J., Salsali A., et al. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care 2010, 33:2217-2224.
11. Bailey C.J., Gross J.L., Pieters A., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:2223-2233.
12. Wilding J.P.H., Norwood P., T'joen C., et al. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers. Applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656-1662.
13. Komoroski B., Vachharajani N., Boulton D., et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009, 85:520-526.
14. Komoroski B., Vachharajani N., Feng Y., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:513-519.
15. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling US Dept of Health and Human Services. Food and Drug Adminstration, Accessed April 12, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf.
16. Obermeier M., Yao M., Khanna A., et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010, 38:405-414.
17. Fraser A., Harris R., Sattar N., et al. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
18. Harris E. Elevated liver function tests in type 2 diabetes. Clin Diabetes 2010, 23:115-119.
19. Glucophage [prescribing information] Princeton, NJ: Bristol-Myers Squibb Company, Accessed February 16, 2010. http://packageinserts.bms.com/pi/pi_glucophage.pdf.
20. Amaryl [prescribing information] Bridgewater, NJ: Sanofi-aventis U.S. LLC, Accessed March 9, 2010. http://products.sanofi-aventis.us/amaryl/amaryl.pdf.
21. Prandin [prescribing information] Princeton, NJ: Novo Nordisk Inc, Accessed September 8, 2010. http://www.prandin.com/docs/prandin_insert.pdf.
22. Actos [prescribing information] Deerfield, IL: Takeda Pharmaceuticals America, Inc, Accessed March 9, 2010. http://www.actos.com/actospro/prescrbinginfo.aspx.
23. Figg W.D., Dukes G.E., Lesesne H.R., et al. Comparison of quantitative methods to assess hepatic function: Pugh's classification, indocyanine green, antipyrine, and dextromethorphan. Pharmacotherapy 1995, 15:693-700.
24. Noncompartmental analysis based on statistical moment theory. Pharmacokinetics 1982, 409-418. Marcel Dekker, Inc, New York, NY. 2nd ed. M. Gibaldi, D. Perrier (Eds.).
25. Congiu M., Mashford M.L., Slavin J.L., Desmond P.V. UDP glucuronosyltransferase mRNA levels in human liver disease. Drug Metab Dispos 2002, 30:129-134.
26. Kroemer H.K., Klotz U. Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 1992, 23:292-310.
27. McGurk K.A., Brierley C.H., Burchell B. Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 1998, 55:1005-1012.
28. Takizawa D., Hiraoka H., Goto F., et al. Human kidneys play an important role in the elimination of propofol. Anesthesiology 2005, 102:327-330.
29. Parker G., Bullingham R., Kamm B., Hale M. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996, 36:332-344.
30. List J.F., Woo V., Morales E., et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650-657.